Vial Announces Dosing of First Patient in Phase 1 Healthy Volunteer Trial
Vial Logo
Back to Resources
  • Videos

Dr. Lee Kaplan MD, Director of Dartmouth Health’s Weight and Wellness Center, suggests new MoAs to tackle the GI intolerance of GLP-1s and highlights Vial’s INHBE siRNA program as a promising target to compliment and potentially enhance current treatments.

Discover Vial’s INHBE siRNA program: vial.com/inhbe-activin-e/

View on Linkedin

More Resources

Could the next generation of obesity treatments help preserve muscle and enhance fat loss? Dr. Tim Garvey (UAB) shares how INHBE inhibition could complement GLP-1 therapies for broader benefit.

Dr. Jens Juul Holst, Professor at the Department of Biomedical Sciences and Senior Group Leader at Novo Nordisk Foundation Center for Basic Metabolic Research on the next breakthroughs in obesity treatment.

Vial’s INHBE siRNA is designed to block Activin E signaling and increase lipolysis for fat-selective weight loss selective fat reduction and muscle preservation is a profile with meaningful clinical potential. Dr. Massimo Volpe, Professor of Cardiology at the University of Rome Sapienza, shares his perspective on why this approach could transform patient care.

Connect with us.

Interested in receiving a proposal from Vial? Leave us a message and some of your contact info and we’ll be in touch with you shortly.

This field is for validation purposes and should be left unchanged.
Name(Required)
By submitting, you are agreeing to our terms and privacy policy

Contact Us

This field is for validation purposes and should be left unchanged.
Name(Required)
By submitting, you are agreeing to our terms and privacy policy